Results from phase II ACE-CL-001 trial and Phase III ASCEND trials shows long-term efficacy of Calquence in chronic lymphocytic leukaemia.- AstraZeneca
Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib), from AstraZeneca, in… read more.